0.09
-0.0101(-10.10%)
Currency In USD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
17
First IPO Date
June 08, 2018
| Name | Title | Pay | Year Born |
| Dr. Lakshmi P. Kotra BPHARM, Ph.D. | Chief Executive Officer of Lucid & Director | 144,724 | 1971 |
| Mr. Zeeshan Saeed | Founder, Chief Executive Officer, President & Executive Co-Chairman | 222,625 | 1970 |
| Dr. Andrzej Chruscinski M.D., Ph.D. | Vice President of Clinical & Scientific Affairs of Lucid | 110,304 | N/A |
| Mr. Kevin Cassidy | Vice President of Quality-Lucid | 144,822 | N/A |
| Mr. Nathan Coyle CPA | Chief Financial Officer | 178,208 | 1981 |
| Mr. Anthony John Durkacz | Founder & Executive Co-Chairman | 222,625 | 1976 |
| Mr. Donal Carroll CPA | Chief Operating Officer | 225,625 | 1977 |
| Ms. Maryann Adesso | Corporate Secretary | 0 | N/A |
| Randell Mack | President of FSD BioSciences | 0 | N/A |
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.